• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于Zr免疫正电子发射断层扫描(Zr-immuno-PET)的Patlak线性化准确性和精确性的最佳成像时间点:一项模拟研究

Optimal imaging time points considering accuracy and precision of Patlak linearization for Zr-immuno-PET: a simulation study.

作者信息

Wijngaarden Jessica E, Huisman Marc C, Pouw Johanna E E, Menke-van der Houven van Oordt C Willemien, Jauw Yvonne W S, Boellaard Ronald

机构信息

Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Boelelaan 1117, Amsterdam, The Netherlands.

Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.

出版信息

EJNMMI Res. 2022 Sep 5;12(1):54. doi: 10.1186/s13550-022-00927-6.

DOI:10.1186/s13550-022-00927-6
PMID:36065038
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9445120/
Abstract

PURPOSE

Zirconium-89-immuno-positron emission tomography (Zr-immuno-PET) has enabled visualization of zirconium-89 labelled monoclonal antibody (Zr-mAb) uptake in organs and tumors in vivo. Patlak linearization of Zr-immuno-PET quantification data allows for separation of reversible and irreversible uptake, by combining multiple blood samples and PET images at different days. As one can obtain only a limited number of blood samples and scans per patient, choosing the optimal time points is important. Tissue activity concentration curves were simulated to evaluate the effect of imaging time points on Patlak results, considering different time points, input functions, noise levels and levels of reversible and irreversible uptake.

METHODS

Based on Zr-mAb input functions and reference values for reversible (V) and irreversible (K) uptake from literature, multiple tissue activity curves were simulated. Three different Zr-mAb input functions, five time points between 24 and 192 h p.i., noise levels of 5, 10 and 15%, and three reference K and V values were considered. Simulated K and V were calculated (Patlak linearization) for a thousand repetitions. Accuracy and precision of Patlak linearization were evaluated by comparing simulated K and V with reference values.

RESULTS

Simulations showed that K is always underestimated. Inclusion of time point 24 h p.i. reduced bias and variability in V, and slightly reduced bias and variability in K, as compared to combinations of three later time points. After inclusion of 24 h p.i., minimal differences were found in bias and variability between different combinations of later imaging time points, despite different input functions, noise levels and reference values.

CONCLUSION

Inclusion of a blood sample and PET scan at 24 h p.i. improves accuracy and precision of Patlak results for Zr-immuno-PET; the exact timing of the two later time points is not critical.

摘要

目的

锆 - 89免疫正电子发射断层扫描(Zr - 免疫PET)能够在体内可视化锆 - 89标记的单克隆抗体(Zr - mAb)在器官和肿瘤中的摄取情况。通过在不同日期采集多个血样和PET图像,对Zr - 免疫PET定量数据进行Patlak线性化处理,可分离可逆摄取和不可逆摄取。由于每位患者能够采集的血样和扫描次数有限,因此选择最佳时间点至关重要。考虑不同的时间点、输入函数、噪声水平以及可逆和不可逆摄取水平,模拟组织活性浓度曲线以评估成像时间点对Patlak结果的影响。

方法

基于Zr - mAb输入函数以及文献中可逆摄取(V)和不可逆摄取(K)的参考值,模拟了多条组织活性曲线。考虑了三种不同的Zr - mAb输入函数、接种后24至192小时之间的五个时间点、5%、10%和15%的噪声水平以及三个参考K和V值。对模拟的K和V进行了一千次重复计算(Patlak线性化)。通过将模拟的K和V与参考值进行比较,评估Patlak线性化的准确性和精密度。

结果

模拟结果表明,K始终被低估。与三个较晚时间点的组合相比,纳入接种后24小时的时间点可降低V的偏差和变异性,并略微降低K的偏差和变异性。纳入接种后24小时的时间点后,尽管输入函数、噪声水平和参考值不同,但在较晚成像时间点的不同组合之间,偏差和变异性的差异极小。

结论

在接种后24小时采集血样和进行PET扫描可提高Zr - 免疫PET的Patlak结果的准确性和精密度;后两个时间点的确切时间并不关键。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/14eebb9df4f7/13550_2022_927_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/6747be991c73/13550_2022_927_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/94d5205de0a2/13550_2022_927_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/14a3941ce193/13550_2022_927_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/3506178fcfda/13550_2022_927_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/14eebb9df4f7/13550_2022_927_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/6747be991c73/13550_2022_927_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/94d5205de0a2/13550_2022_927_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/14a3941ce193/13550_2022_927_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/3506178fcfda/13550_2022_927_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cd4/9445120/14eebb9df4f7/13550_2022_927_Fig5_HTML.jpg

相似文献

1
Optimal imaging time points considering accuracy and precision of Patlak linearization for Zr-immuno-PET: a simulation study.基于Zr免疫正电子发射断层扫描(Zr-immuno-PET)的Patlak线性化准确性和精确性的最佳成像时间点:一项模拟研究
EJNMMI Res. 2022 Sep 5;12(1):54. doi: 10.1186/s13550-022-00927-6.
2
Validation of simplified uptake measures against dynamic Patlak K for quantification of lesional Zr-Immuno-PET antibody uptake.简化摄取测量与动态 Patlak K 对比验证法在定量分析病灶 Zr-免疫 PET 抗体摄取中的应用。
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1897-1905. doi: 10.1007/s00259-023-06151-1. Epub 2023 Feb 23.
3
Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs.联用免疫检查点抑制剂的锆标记免疫正电子发射断层显像:测量健康器官中的靶点结合情况
Cancers (Basel). 2023 Nov 23;15(23):5546. doi: 10.3390/cancers15235546.
4
Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo.Zr-免疫 PET:一种用于测量治疗性抗体体内靶标占有率的无创临床工具。
J Nucl Med. 2019 Dec;60(12):1825-1832. doi: 10.2967/jnumed.118.224568. Epub 2019 May 30.
5
Non-specific irreversible Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using Zr-immuno-PET.肿瘤中锆标记单克隆抗体的非特异性不可逆摄取:来自经活检证实为靶阴性肿瘤的锆免疫正电子发射断层扫描证据。
EJNMMI Res. 2024 Feb 15;14(1):18. doi: 10.1186/s13550-024-01079-5.
6
Immuno-PET Imaging to Assess Target Engagement: Experience from Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors.免疫 PET 成像评估靶点结合:Zr-抗 HER3 mAb(GSK2849330)在实体瘤患者中的应用经验。
J Nucl Med. 2019 Jul;60(7):902-909. doi: 10.2967/jnumed.118.214726. Epub 2019 Feb 7.
7
Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.基于计数减少的临床图像分析,放射性核素标记抗体免疫 PET 的噪声诱导变异性。
Mol Imaging Biol. 2018 Dec;20(6):1025-1034. doi: 10.1007/s11307-018-1200-4.
8
Noise sensitivity of Zr-Immuno-PET radiomics based on count-reduced clinical images.基于计数减少的临床图像的锆免疫正电子发射断层显像放射组学的噪声敏感性
EJNMMI Phys. 2022 Mar 3;9(1):16. doi: 10.1186/s40658-022-00444-4.
9
[Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model.[锆]人前列腺干细胞抗原敲入(hPSCA KI)同基因模型中前列腺癌的免疫正电子发射断层扫描
Mol Imaging Biol. 2020 Apr;22(2):367-376. doi: 10.1007/s11307-019-01386-7.
10
How to obtain the image-derived blood concentration from Zr-immuno-PET scans.如何从锆免疫正电子发射断层扫描(Zr-immuno-PET)中获取图像衍生的血药浓度。
EJNMMI Phys. 2024 Feb 7;11(1):16. doi: 10.1186/s40658-024-00621-7.

引用本文的文献

1
Advances and challenges in immunoPET methodology.免疫正电子发射断层扫描(immunoPET)方法的进展与挑战
Front Nucl Med. 2024 Feb 19;4:1360710. doi: 10.3389/fnume.2024.1360710. eCollection 2024.
2
Molecular imaging supports the development of multispecific cancer antibodies.分子成像支持多特异性癌症抗体的开发。
Nat Rev Clin Oncol. 2024 Dec;21(12):852-866. doi: 10.1038/s41571-024-00946-3. Epub 2024 Sep 26.
3
The development process of 'fit-for-purpose' imaging biomarkers to characterize the tumor microenvironment.用于表征肿瘤微环境的“适用型”成像生物标志物的开发过程。

本文引用的文献

1
Use of population input functions for reduced scan duration whole-body Patlak F-FDG PET imaging.使用群体输入函数以缩短扫描时间进行全身Patlak F-FDG PET成像。
EJNMMI Phys. 2021 Feb 5;8(1):11. doi: 10.1186/s40658-021-00357-8.
2
The Role of Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals.Zr 免疫 PET 在生物制药开发中的导航和风险降低作用。
J Nucl Med. 2021 Apr;62(4):438-445. doi: 10.2967/jnumed.119.239558. Epub 2020 Dec 4.
3
Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo.
Front Med (Lausanne). 2024 May 16;11:1347267. doi: 10.3389/fmed.2024.1347267. eCollection 2024.
4
Non-specific irreversible Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using Zr-immuno-PET.肿瘤中锆标记单克隆抗体的非特异性不可逆摄取:来自经活检证实为靶阴性肿瘤的锆免疫正电子发射断层扫描证据。
EJNMMI Res. 2024 Feb 15;14(1):18. doi: 10.1186/s13550-024-01079-5.
5
ImmunoPET imaging-based pharmacokinetic profiles of an antibody and its Fab targeting endothelin A receptors on glioblastoma stem cells in a preclinical orthotopic model.免疫 PET 成像示基于抗体及其针对胶质母细胞瘤干细胞内皮素 A 受体的 Fab 片段的药代动力学在临床前原位模型中的研究。
Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3192-3201. doi: 10.1007/s00259-023-06268-3. Epub 2023 Jun 7.
6
Validation of simplified uptake measures against dynamic Patlak K for quantification of lesional Zr-Immuno-PET antibody uptake.简化摄取测量与动态 Patlak K 对比验证法在定量分析病灶 Zr-免疫 PET 抗体摄取中的应用。
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1897-1905. doi: 10.1007/s00259-023-06151-1. Epub 2023 Feb 23.
Zr-免疫 PET:一种用于测量治疗性抗体体内靶标占有率的无创临床工具。
J Nucl Med. 2019 Dec;60(12):1825-1832. doi: 10.2967/jnumed.118.224568. Epub 2019 May 30.
4
Pharmacokinetics and Biodistribution of a [Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.[Zr]Zr-DFO-MSTP2109A 抗 STEAP1 抗体在转移性去势抵抗性前列腺癌患者中的药代动力学和生物分布。
Mol Pharm. 2019 Jul 1;16(7):3083-3090. doi: 10.1021/acs.molpharmaceut.9b00326. Epub 2019 May 31.
5
The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans.通过正电子发射断层扫描(PET)成像技术在人体中评估新型生物制药药物平台AlbudAb的生物分布和清除情况。
EJNMMI Res. 2019 May 21;9(1):45. doi: 10.1186/s13550-019-0514-9.
6
Immuno-PET Imaging to Assess Target Engagement: Experience from Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors.免疫 PET 成像评估靶点结合:Zr-抗 HER3 mAb(GSK2849330)在实体瘤患者中的应用经验。
J Nucl Med. 2019 Jul;60(7):902-909. doi: 10.2967/jnumed.118.214726. Epub 2019 Feb 7.
7
Monoclonal antibodies in cancer immunotherapy.癌症免疫疗法中的单克隆抗体。
Mol Biol Rep. 2018 Dec;45(6):2935-2940. doi: 10.1007/s11033-018-4427-x. Epub 2018 Oct 11.
8
Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.基于计数减少的临床图像分析,放射性核素标记抗体免疫 PET 的噪声诱导变异性。
Mol Imaging Biol. 2018 Dec;20(6):1025-1034. doi: 10.1007/s11307-018-1200-4.
9
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.人表皮生长因子受体 2 靶向 Zr-帕妥珠单抗 PET/CT 用于人体的首次研究:乳腺癌患者的剂量学和临床应用。
J Nucl Med. 2018 Jun;59(6):900-906. doi: 10.2967/jnumed.117.202010. Epub 2017 Nov 16.
10
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for Zr-Trastuzumab in Patients with Esophagogastric Cancer.Zr-曲妥珠单抗在食管胃结合部癌患者中的药代动力学、生物分布和辐射剂量学。
J Nucl Med. 2018 Jan;59(1):161-166. doi: 10.2967/jnumed.117.194555. Epub 2017 Jun 21.